SynthesisFrontiers in immunology2026
Efficacy and safety of thymosin combined with anticancer therapy for esophageal cancer: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to comprehensively evaluate the clinical efficacy, impact on immune function, and safety of thymosin combined with anticancer therapy for esophageal cancer (EC) patients. Methods: We systematically searched Chinese and English databases to identify randomized controlled trials (RCTs) evaluating thymosin combined with standard anticancer therapy for EC. Meta-analysis was performed using Review Manager 5.4. Sensitivity analysis and publication bias assessment were conducted using Stata 18.0. TSA was further employed to validate the reliability of primary outcomes. Evidence quality was assessed using GRADE system. Results: A total of 18 RCTs (1,272 patients) were included. Meta-analysis demonstrated that compared with standard anticancer therapy alone, combined thymosin therapy significantly improved Objective Response Rate (ORR) (RR = 1.27, 95% CI: 1.17-1.39) and Disease Control Rate (DCR) (RR = 1.13, 95% CI: 1.07-1.19), and improved 1-year survival rate (RR = 1.36, 95% CI: 1.19-1.56), 2-year survival rate (RR = 1.47, 95% CI: 1.12-1.92), and 3-year survival rate (RR = 1.42, 95% CI: 1.07-1.90). Regarding immune function, the treatment group exhibited a higher CD3 Conclusion: Current evidence suggests that combination of thymosin with anticancer therapy for EC may enhance antitumor efficacy, improve patients' immune function, and reduce toxicity associated with conventional treatments. However, given limited quality of RCTs and presence of publication bias, these conclusions require validation through additional large-scale, high-quality prospective research. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier PROSPERO CRD420261282381.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.